Back | Next |
home / stock / cvm / cvm message board
Subject | By | Source | When |
---|---|---|---|
I didnt expect PPS to be in the | sushifishman | investorshub | 04/24/2023 6:27:21 PM |
Nothing new in it that we didn't already | drkazmd65 | investorshub | 04/24/2023 1:32:36 PM |
u must be on the wrong board | tarius729 | investorshub | 04/23/2023 6:06:47 AM |
For the true $CVM Longs: | sushifishman | investorshub | 04/22/2023 7:12:53 PM |
Media blitz coming Monday (4/24) and Tuesday (4/25) | sushifishman | investorshub | 04/22/2023 4:50:37 PM |
Spell check | thinkingonlygreen | investorshub | 04/21/2023 9:07:28 PM |
Latest presentation: https://cel-sci.com/wp-content/uploads/2023/04/CEL-SCI | Phoenix2020 | investorshub | 04/21/2023 6:09:34 PM |
Also: even a blind squirrel occasionally finds a | Foxxycleopatra | investorshub | 04/20/2023 10:05:23 AM |
Oh Canada The pump before the offering after May 23 | sushifishman | investorshub | 04/19/2023 1:15:39 PM |
Impact News? Perhaps! Pre-Market likes it. | rdneum | investorshub | 04/19/2023 1:08:17 PM |
Indeed! I love this board | sushifishman | investorshub | 04/18/2023 2:34:05 PM |
How does that old saying go - even | drkazmd65 | investorshub | 04/18/2023 12:47:54 PM |
and $CVM | tarius729 | investorshub | 04/18/2023 3:55:14 AM |
Boom Da Boom | sushifishman | investorshub | 04/17/2023 2:32:41 PM |
It's going to take patience and time | DocKB | investorshub | 04/15/2023 1:11:09 PM |
The Q is triggered on StockTwits Thats gotta be | sushifishman | investorshub | 04/15/2023 12:04:02 PM |
Secondary 101: Path to The Late May Offering The | sushifishman | investorshub | 04/15/2023 11:51:17 AM |
Your opinion has been noted, examined, and tossed | drkazmd65 | investorshub | 04/14/2023 3:41:23 PM |
Because this position in $CVM, and in a | drkazmd65 | investorshub | 04/14/2023 2:31:11 PM |
Patience and time in a penny stock is | fung_derf | investorshub | 04/14/2023 2:13:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...